(Alliance News) - GSK PLC on Wednesday said it reached two confidential settlements regarding the Zantac case in California State Court. The London-based pharmaceutical company said the cases ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of ...

GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and ...

LONDON, UK I 12, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal ...

LONDON, UK I 11, 2024 I GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial.

Healthcare comms agency, London Agency, has welcomed Theodore Seng and Rebecca Dawson to its team.The announcement:London ...

London: GSK plc has announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...

London stocks closed in positive territory on Friday, bolstered by hopes of an interest rate cut in the United States, ...

GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses again ...